PHASE I CLINICAL TRIAL OF AUTOLOGOUS T-CELLS GENETICALLY ENGINEERED WITH A CHIMERIC RECEPTOR TO TARGET THE FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) IN PATIENTS WITH RECURRENT OVARIAN CANCER (OVCA)

Category Primary study
JournalJOURNAL FOR IMMUNOTHERAPY OF CANCER
Year 2022
This article has no abstract
Epistemonikos ID: 880da23453784cc46eb7fe8a3c41fcac5f6b785a
First added on: Feb 15, 2025